Bailey Dove/Victrelis
From Proteopedia
Contents |
Victrelis
Victrelis (boceprevir) is an antiviral Hepatitis C medication approved by the United States Food and Drug Administration in 2011. Victrelis is an inhibitor of the non-structural protein 3 (NS3) serine protease. The medication inhibits viral replication in Hepatitis C virus infected cells. [1]
Disease
Hepatitis C is a blood-borne, single-stranded RNA virus that attacks the liver[2][3]. If left untreated, an acute Hepatitis C infection could lead to chronic hepatitis, liver failure, or liver cancer [4].
Serine Protease NS3
Double-stranded RNA (dsRNA), which is a common intermediate that is found in any given life cycle of many viruses, is a trigger of the immune response[5].
</StructureSection>
References
- ↑ Merck & Co., Inc. (n.d.) Highlights of prescribing information. Retrieved from https://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf
- ↑ Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004 Feb;12(2):96-102. PMID:15036326 doi:http://dx.doi.org/10.1016/j.tim.2003.12.005
- ↑ Centers for Disease Control and Prevention. (2015). Viral Hepatitis - Hepatitis C Information. Retrieved from http://www.cdc.gov/hepatitis/hcv/index.htm
- ↑ Zhu Y, Chen S. Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol. 2013 Dec 21;19(47):8963-73. doi: 10.3748/wjg.v19.i47.8963. PMID:24379621 doi:http://dx.doi.org/10.3748/wjg.v19.i47.8963
- ↑ Robalino J, Browdy CL, Prior S, Metz A, Parnell P, Gross P, Warr G. Induction of antiviral immunity by double-stranded RNA in a marine invertebrate. J Virol. 2004 Oct;78(19):10442-8. PMID:15367610 doi:http://dx.doi.org/10.1128/JVI.78.19.10442-10448.2004
